Tesis
Análise das recidivas de malária causada por Plasmodium vivax no município de Porto Velho, Rondônia, 2009
Fecha
2012-11-27Registro en:
SIMÕES, Luciano Rodrigues. Análise das recidivas de malária causada por Plasmodium vivax no município de Porto Velho, Rondônia, 2009. 2012. 76 f. Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Mato Grosso, Faculdade de Medicina, Cuiabá, 2012.
Autor
Fontes, Cor Jesus Fernandes
http://lattes.cnpq.br/5971254060419331
Fontes, Cor Jesus Fernandes
199.869.476-34
http://lattes.cnpq.br/5971254060419331
Ignotti, Eliane
559.548.479-91
http://lattes.cnpq.br/4407130301215869
199.869.476-34
Tada, Mauro Shugiro
457.869.251-53
http://lattes.cnpq.br/7333101309777380
Institución
Resumen
In 2011, 293,794 malaria cases were registered in Brazil, with more than 85% caused by
Plasmodium vivax. The state of Rondonia had the third highest incidence of the disease. The
term recurrence of a disease refers to the recurrence of symptoms after a period of time longer
or shorter since the recovery or cure. Recurrence of malaria can be caused by treatment
failure, reactivation of dormant form of the parasite or reinfection by a mosquito bite,
classified as recrudescence, relapse and reinfection, respectively. The National Malaria
Control Programme defines as P. vivax recrudescence the recurrence of parasitemia between 7
to 28 days after the beginning of treatment. As P. vivax relapse the recurrence ocurring
between 29 and 60 days and reinfection as the reappearance of the parasitemia after 60 days
of the treatment. This study described the recurrence risk for malaria caused by P. vivax in the
city of Porto Velho (RO) in 2009. An open retrospective cohort study was performed, using
the malaria information registered in the Epidemiological Information System for the
Surveillance of Malaria (SIVEP-Malaria). In 2009, there were 23.365 P. vivax malaria cases
in Porto Velho, 23% of them having P. vivax malaria recurrence during the year of study. The
largest proportion (67%) of patients who recurred had a single episode of recurrence, although
several patients have experienced multiple recurrences in the year. The incidence density of
recurrence observed in the study period was 45.1/100 person-years, mostly occurring between
the 4th and 13th week after treatment initiation. Being male, having less time of symptoms
and having a higher level of parasitemia at diagnosis of P. vivax malaria increase the risk of
recurrence during the follow-up. The found associations were 11% and 15% of risk increasing
for males and for higher levels of parasitemia at diagnosis, respectively, and 10% of risk
reduction for longer time of onset of symptoms. However, these low values of the risk
measures represent a very low clinical relevance of these associations, undermining its causal
relationship to predict the incidence of P. vivax recurrence or to justify decision making in
public health.